Head and Neck Squamous Cell Carcinoma — Oral Rigosertib for Squamous Cell Carcinoma
Citation(s)
A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma